New Data Suggests Pfizer’s COVID Pill Paxlovid Won’t Benefit Low-Risk, Vaccinated Patients

New Data Suggests Pfizer's COVID Pill Paxlovid Won't Benefit Low-Risk, Vaccinated Patients

Pfizer’s COVID-19 antiviral treatment pill, Paxlovid, has shown evidence that it may not be beneficial for individuals who are vaccinated, according to the pharmaceutical company.

목요일에, the company released the results of a new study on Paxlovid. Researchers analyzed 721 vaccinated adults with at least one risk factor for COVID and found that there was anon-significantrisk reduction in hospitalization or death when treated with the antiviral pill.

하지만, experts assure the results maintain that the use of Paxlovid can significantly reduce severe symptoms of COVID for high-risk patients who have underlying health conditions.

Paxlovid is something that is targeted towards high-risk individuals, so the fact that it doesn’t have a benefit to low-risk individuals isn’t surprising to me,” 박사. Amesh Adalja, infectious disease specialist at the Johns Hopkins University Center for Health Security, 말했다 ABC 뉴스.

With up to 40-50% of people around the world estimated to be high risk, we believe there remains a significant unmet need for treatment options to help combat this disease, and we will continue to prioritize efforts to advance the development of Paxlovid,” Pfizer CEO Albert Bourla said in a release.

스토리를 놓치지 마세요. 사람들의 무료 일간 뉴스레터 PEOPLE이 제공하는 최고의 최신 정보를 유지하기 위해, 흥미진진한 유명인 뉴스부터 흥미진진한 스토리까지.


Pfizer’s COVID-19 anti-viral treatment Paxlovid
| 신용 거래: Pfizer/AFP via Getty

The new data comes one week after the 식품의약국 revised the emergency use authorization for Paxlovid, allowing pharmacists across the United States to prescribe the COVID treatment to eligible patients.

Individuals who test positive for COVID and want to determine their eligibility to take Paxlovid can bring a list of their current medications and health records detailing kidney or liver problems to their pharmacist for review. Patients with reduced kidney function may require a lower dose of Paxlovid, per the FDA.

The FDA recognizes the important role pharmacists have played and continue to play in combatting this pandemic,” 박사가 말했다. 파트리지아 카바조니, director for the FDA’s Center for Drug Evaluation and Research, said in a release. “Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of COVID-19.

4월에 다시, the Biden Administration announced plans for Paxlovid to be madewidely available,” 박사. Ashish Jha, White House Covid-19 Response Coordinator, said on Twitter.

What are we working on? A lot more places where Pax will be available including more test-to-treat, education for providers to use it more regularly for eligible patients, 그리고 더,” Jha 썼다 당시. “Paxlovid is extraordinarily effective at preventing bad outcomes. We’re getting it out to the American people.

The Test to Treat initiative was launched earlier this year in order to give Americans easy access to COVID treatment, ~와 함께 one-stop sites to get tested for COVID-19 and then be prescribed with free oral antiviral medications.

The FDA first granted Paxlovid emergency use authorization 11 월 2021 for use in patients age 12 기저 질환으로 인해 중증 COVID-19 발병 위험이 높은 고령자.

Each pack of Paxlovid contains 30 tablets taken over the course of five days. 에 따르면 Yale Medicine, the pill is effective against the highly contagious COVID-19 omicron variant.

Yale Medicine infectious diseases specialist, Scott Roberts, believes the pillshows clear benefit.

I think it is the beginning of a game-changer,” said Roberts. “It’s really our first efficacious oral antiviral pill for this virus. It shows clear benefit, and it really can prevent hospitalization and death in people who are at high risk.